CA2900454A1 - Pharmaceutical compositions comprising vesicles - Google Patents

Pharmaceutical compositions comprising vesicles Download PDF

Info

Publication number
CA2900454A1
CA2900454A1 CA2900454A CA2900454A CA2900454A1 CA 2900454 A1 CA2900454 A1 CA 2900454A1 CA 2900454 A CA2900454 A CA 2900454A CA 2900454 A CA2900454 A CA 2900454A CA 2900454 A1 CA2900454 A1 CA 2900454A1
Authority
CA
Canada
Prior art keywords
vesicle
animal
vesicles
composition
bacterial
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2900454A
Other languages
English (en)
French (fr)
Inventor
Guido Grandi
Alberto Grandi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GlaxoSmithKline Biologicals SA
Externautics SpA
Original Assignee
GlaxoSmithKline Biologicals SA
Externautics SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by GlaxoSmithKline Biologicals SA, Externautics SpA filed Critical GlaxoSmithKline Biologicals SA
Publication of CA2900454A1 publication Critical patent/CA2900454A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005Wall or coating material
    • A61K9/5063Compounds of unknown constitution, e.g. material from plants or animals
    • A61K9/5068Cell membranes or bacterial membranes enclosing drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/127Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Botany (AREA)
  • Virology (AREA)
  • Cell Biology (AREA)
  • Dispersion Chemistry (AREA)
  • Rheumatology (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Obesity (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Communicable Diseases (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Emergency Medicine (AREA)
CA2900454A 2013-02-07 2014-02-06 Pharmaceutical compositions comprising vesicles Abandoned CA2900454A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP13154463.7 2013-02-07
EP13154463 2013-02-07
PCT/EP2014/052370 WO2014122232A1 (en) 2013-02-07 2014-02-06 Pharmaceutical compositions comprising vesicles

Publications (1)

Publication Number Publication Date
CA2900454A1 true CA2900454A1 (en) 2014-08-14

Family

ID=47681775

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2900454A Abandoned CA2900454A1 (en) 2013-02-07 2014-02-06 Pharmaceutical compositions comprising vesicles

Country Status (7)

Country Link
US (1) US20160120818A1 (https=)
EP (1) EP2953620A1 (https=)
JP (1) JP2016507543A (https=)
CN (1) CN105163724A (https=)
BR (1) BR112015018877A2 (https=)
CA (1) CA2900454A1 (https=)
WO (1) WO2014122232A1 (https=)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102396026B1 (ko) * 2014-01-21 2022-05-09 안자리움 바이오사이언시스 아게 하이브리도좀, 이를 포함하는 조성물, 이의 제조 방법 및 이의 용도
AU2015326407C1 (en) * 2014-10-03 2021-06-24 Engeneic Molecular Delivery Pty Ltd Enhanced loading of intact, bacterially derived vesicles with small molecule compounds
AU2017226956A1 (en) * 2016-03-03 2018-10-11 Institut Gustave Roussy PTPS-based vaccines against cancer
CN110248645B (zh) * 2016-12-29 2022-04-26 韩国科学技术研究院 基于外来体的抗癌剂
EP3678693A1 (en) 2017-09-08 2020-07-15 Evelo Biosciences, Inc. Bacterial extracellular vesicles
BR102018008194A2 (pt) * 2018-04-24 2020-07-07 Universidade De São Paulo - Usp. kit farmacêutico e seus usos
WO2019210189A1 (en) * 2018-04-26 2019-10-31 University Of Louisville Research Foundation, Inc. Edible plant exosome-like nanovectors for vaccination
US11541105B2 (en) 2018-06-01 2023-01-03 The Research Foundation For The State University Of New York Compositions and methods for disrupting biofilm formation and maintenance
US12397047B2 (en) * 2019-01-09 2025-08-26 Exocure Sweden Ab Bacteria-derived vesicles and uses thereof
CN110367202B (zh) * 2019-06-20 2021-11-02 广东医科大学附属医院 一种肠菌外膜囊泡在制备痴呆动物模型中的应用
US20220378902A1 (en) * 2019-08-22 2022-12-01 Sichuan University Bacterial membrane vesicles, and separation and preparation system and method therefor
EP4013392B1 (en) 2019-09-13 2026-04-29 Exocure Sweden AB Use of ghost nanovesicles as therapeutics
CN111521826A (zh) * 2020-05-21 2020-08-11 江海松 外周血外泌体中Notch3蛋白作为分子标记的应用及一种检测试剂盒
WO2022154149A1 (ko) * 2021-01-14 2022-07-21 (주)엑솔런스 세포외소포체를 이용한 백신 조성물
WO2023097652A1 (en) * 2021-12-03 2023-06-08 National Center For Nanoscience And Technology An engineered cell and application thereof
KR20240010702A (ko) * 2022-07-13 2024-01-24 (주)엑솔런스 항원 단백질 또는 상기 단백질을 암호화하는 유전자를포함하는 세포외소포체 및 그의 용도
CN115350161B (zh) * 2022-08-19 2024-04-16 沈阳药科大学 基于工程化益生菌外膜囊泡包被纳米酶递送系统及其制备方法和应用
CN117065041B (zh) * 2023-04-04 2024-02-27 山东大学 一种包被载药脂质纳米粒的外膜囊泡及其制备方法和应用
CN120789140B (zh) * 2025-09-12 2026-04-10 湖北医药学院 一种治疗结肠炎的联合用药物及其应用

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6180111B1 (en) 1995-05-18 2001-01-30 University Of Maryland Vaccine delivery system
US6645503B1 (en) 1998-03-10 2003-11-11 Wyeth Holdings Corporation Antigenic conjugates of conserved lipopolysaccharides of gram negative bacteria
US6248329B1 (en) * 1998-06-01 2001-06-19 Ramaswamy Chandrashekar Parasitic helminth cuticlin nucleic acid molecules and uses thereof
AU762369B2 (en) 1998-11-03 2003-06-26 De Staat Der Nederlanden Vertegenwoordigd Door De Minister Van Welzijn, Volksgezonheid En Cultuur LPS with reduced toxicity from genetically modified gram negative bacteria
US6531131B1 (en) 1999-08-10 2003-03-11 The United States Of America As Represented By The Department Of Health And Human Services Conjugate vaccine for Neisseria meningitidis
AU1917501A (en) 1999-11-12 2001-06-06 University Of Iowa Research Foundation, The Control of neisserial membrane synthesis
PT2289545T (pt) * 2000-01-17 2016-09-06 Glaxosmithkline Biologicals Sa Vacina de omv suplementada contra meningococos
NO20002828D0 (no) 2000-06-02 2000-06-02 Statens Inst For Folkehelse Proteinholdig vaksine mot Neisseria meningtidis serogruppe samt fremgangsmÕte ved fremstilling derav
ES2519440T3 (es) 2000-07-27 2014-11-07 Children's Hospital & Research Center At Oakland Vacunas para la protección de amplio espectro contra enfermedades causadas por Neisseria meningitidis
GB0130123D0 (en) * 2001-12-17 2002-02-06 Microbiological Res Agency Outer membrane vesicle vaccine and its preparation
US20060057160A1 (en) 2002-08-02 2006-03-16 Ralph Biemans Vaccine composition
GB0220194D0 (en) 2002-08-30 2002-10-09 Chiron Spa Improved vesicles
GB0316560D0 (en) 2003-07-15 2003-08-20 Chiron Srl Vesicle filtration
DK2992901T3 (da) * 2004-02-02 2020-01-27 Engeneic Molecular Delivery Pty Ltd Sammensætninger og fremgangsmåder til målrettet in vitro- og in vivo-medicinlevering til pattedyrceller via bakterielt afledte intakte miniceller
GB0419627D0 (en) 2004-09-03 2004-10-06 Chiron Srl Immunogenic bacterial vesicles with outer membrane proteins
GB0424092D0 (en) * 2004-10-29 2004-12-01 Chiron Srl Immunogenic bacterial vesicles with outer membrane proteins
WO2006081259A2 (en) 2005-01-27 2006-08-03 Children's Hospital & Research Center At Oakland Gna1870-based vesicle vaccines for broad spectrum protection against diseases caused by neisseria meningitidis
EP2254586B1 (en) * 2008-02-22 2015-04-08 Agency For Science, Technology And Research (A*star) Mesenchymal stem cell particles
CN102596177B (zh) * 2009-07-01 2014-05-28 阿昂梅迪克斯公司 来源于有核哺乳动物细胞的微囊泡及其应用
GB0917003D0 (en) 2009-09-28 2009-11-11 Novartis Vaccines Inst For Global Health Srl Purification of bacterial vesicles

Also Published As

Publication number Publication date
CN105163724A (zh) 2015-12-16
BR112015018877A2 (pt) 2017-08-22
WO2014122232A1 (en) 2014-08-14
EP2953620A1 (en) 2015-12-16
US20160120818A1 (en) 2016-05-05
JP2016507543A (ja) 2016-03-10

Similar Documents

Publication Publication Date Title
US20160120818A1 (en) Pharmaceutical compositions comprising vesicles
JP7812573B2 (ja) 生体高分子薬を送達するための組成物及び方法
JP7730867B2 (ja) 結合エピトープを含有する融合タンパク質を封入する粒子
De Serrano et al. Liposomal vaccine formulations as prophylactic agents: design considerations for modern vaccines
Christensen et al. A cationic vaccine adjuvant based on a saturated quaternary ammonium lipid have different in vivo distribution kinetics and display a distinct CD4 T cell-inducing capacity compared to its unsaturated analog
US12054521B2 (en) FhuD2 fusion proteins for the outer membrane vesicle (OMV) delivery of heterologous polypetides and immunogenic compositions thereof
JP2024028876A (ja) 免疫応答を調節可能な金属含有製剤のための組成物および方法
Shariat et al. P5 HER2/neu-derived peptide conjugated to liposomes containing MPL adjuvant as an effective prophylactic vaccine formulation for breast cancer
Gómez et al. Surface coating of PLGA microparticles with protamine enhances their immunological performance through facilitated phagocytosis
RU2578420C2 (ru) Иммуностимулирующие и вакцинные композиции
Rostami et al. Co-utilization of a TLR5 agonist and nano-formulation of HIV-1 vaccine candidate leads to increased vaccine immunogenicity and decreased immunogenic dose: A preliminary study
JP6487850B2 (ja) アジュバント組成物およびこれを含むワクチン組成物、並びにこれらの製造方法
Moore et al. Injectable, ribbon-like microconfetti biopolymer platform for vaccine applications
Kumar et al. Development of soluble inulin microparticles as a potent and safe vaccine adjuvant and delivery system
Wang et al. The mechanism of action of acid-soluble chitosan as an adjuvant in the formulation of nasally administered vaccine against HBV
Yan et al. The effects of salt on the physicochemical properties and immunogenicity of protein based vaccine formulated in cationic liposome
Arias et al. Carnauba wax nanoparticles enhance strong systemic and mucosal cellular and humoral immune responses to HIV-gp140 antigen
Wang et al. A natural IgM hitchhiking strategy for delivery of cancer nanovaccines to splenic marginal zone B cells
Jahan et al. Potentiating antigen specific immune response by targeted delivery of the PLGA-based model cancer vaccine
Blom et al. Virosome-bound antigen enhances DC-dependent specific CD4+ T cell stimulation, inducing a Th1 and Treg profile in vitro
Hu et al. Toll-like receptor 9 agonists as adjuvants for nanoparticle-based nicotine vaccine
Tiwari et al. Viral protein complexed liposomes for intranasal delivery of hepatitis B surface antigen
Kuai et al. Lipid-based nanoparticles for vaccine applications
Gayatri et al. Utilization of Protein and Peptides as Cancer Vaccines: Advancement and Challenges Assessment of Ethnomedicinal Plants: Shiwalik Hills, Himachal Pradesh, India
Pan et al. Nanoadjuvant‐Mediated EV‐Derived Artificial APC to Trigger Protective Immunity Against Virus Infection

Legal Events

Date Code Title Description
FZDE Discontinued

Effective date: 20200206